Compare Quest Diagnostics Inc (DGX) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Li Auto Inc — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Li Auto Inc trades at $12.44 (market cap $12.25B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Li Auto Inc pays none. Which is the better fit depends on your goals.
| DGX | LI | |
|---|---|---|
Market Cap | $22.80B | $12.25B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.02 | $31.80 |
52-Week Low | $166.42 | $11.74 |
Enterprise Value | $28.82B | $1.17B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Li Auto (LI) trades at $12.18, down 0.66% on the day, with a bearish technical signal and mixed earnings history. The company reported a net income margin of -1.66% for 2025 and faces headwinds from domestic competition and aggressive discounting. Recent news highlights delivery updates and new model launches, but the stock remains under pressure amid broader EV sector challenges.
The outlook is cautious with a consensus price target of $14.80, suggesting potential upside, but risks include profitability concerns, competitive pressures, and volatile cash flows. Recovery hinges on successful execution of the L series and global expansion, with FY2025-2026 seen as trough years before potential improvement from 2027.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
